

Inhibitory Effects of Cucurbitane Glycosides and Other Triterpenoids from the Fruit of *Momordica grosvenori* on Epstein–Barr Virus Early Antigen Induced by Tumor Promoter 12-*O*-Tetradecanoylphorbol-13-acetate

MOTOHIKO UKIYA,[‡] TOSHIHIRO AKIHISA,^{*,‡} HARUKUNI TOKUDA,[§]
 MASAKAZU TORIUMI,[‡] TERUO MUKAINAKA,[§] NORIHIRO BANNO,[‡]
 YUMIKO KIMURA,[#] JUN-ICHI HASEGAWA,[‡] AND HOYOKU NISHINO[§]

College of Science and Technology, Nihon University, 1-8 Kanda Surugadai, Chiyoda-ku,
 Tokyo 101-8308, Japan, Department of Biochemistry, Kyoto Prefectural University of Medicine,
 Kamigyo-ku, Kyoto 602-0841, Japan, Ichimaru Pharcos Company Ltd., 318-1 Shinsei, Motosu-gun,
 Gifu 501-0475, Japan, and College of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-shi,
 Chiba 274-8555, Japan

Two new triterpene benzoates, 5-dehydrokarounidiol dibenzoate (**1**) and karounidiol dibenzoate (**2**), and two new triterpene glycosides, 5 α ,6 α -epoxymogroside IE₁ (**8**) and 11-oxomogroside A₁ (**9**), along with 15 known triterpenoids (one triterpene benzoate, **3**; three triterpene mono-ols, **4–6**; one triterpene aglycon, **7**; and 10 triterpene glycosides, **10–19**), were isolated from the ethanol extract of the fruit of *Momordica grosvenori*. The structures of **1**, **2**, **8**, and **9** were determined on the basis of spectroscopic and chemical methods. Among the known triterpene glycosides, mogroside I E₁ (**12**) was a new naturally occurring compound. Eighteen triterpenoids (**2–19**) and 11-oxomogrol (**20**), a hydrolysis product of **9**, were evaluated with respect to their inhibitory effects on the induction of Epstein–Barr virus early antigen (EBV-EA) by 12-*O*-tetradecanoylphorbol-13-acetate (TPA) in Raji cells, which is known to be a primary screening test for antitumor promoters. All of the compounds tested showed potent inhibitory effects on EBV-EA induction (70–100% inhibition at 1 \times 10³ mol ratio/TPA).

KEYWORDS: *Momordica grosvenori*; fruit; Cucurbitaceae; sweet principle; triterpenoids; cucurbitane glycosides; antitumor promoter; Epstein–Barr virus early antigen

INTRODUCTION

The fruit of *Momordica grosvenori* Swingle (Cucurbitaceae) grown in Kwangshi, China, is used as an expectorant as well as a natural sweet food in that country, and many cucurbitane-type triterpene glycosides have been isolated from it and characterized (1–3). We recently reported the isolation and characterization of some cucurbitane glycosides from the roots of *Bryonia dioica* (Cucurbitaceae) and their inhibitory effects on 12-*O*-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation in mice and on the induction of Epstein–Barr virus early antigen (EBV-EA) (4). In continuing our study on the search for potent antitumor promoters in natural resources, we have investigated the triterpenoid constituents of the ethanol extract of *M. grosvenori* fruit. In this paper, we report the isolation

and characterization of 19 compounds from the extract and inhibitory effects on the induction of EBV-EA by TPA of 19 compounds (**2–20**), evaluated in a preliminary screen for their potential cancer chemopreventive activities.

MATERIALS AND METHODS

General Methods. Crystallizations were performed in methanol (MeOH). Melting points were measured on a Yanagimoto micro-melting point apparatus and are uncorrected. Ultraviolet (UV) spectra were determined on a Shimadzu UV-300 spectrometer in ethanol (EtOH). Infrared (IR) spectra were recorded on a JASCO IR-300 IR spectrometer in KBr disks. Nuclear magnetic resonance (NMR) spectra were recorded with a JEOL LA-500 spectrometer at 500 MHz (¹H NMR) and 125 MHz (¹³C NMR) in C₅D₅N or in CDCl₃, and chemical shifts are expressed in δ (ppm) referred to tetramethylsilane (TMS). Fast atom bombardment mass spectra (FABMS) and high-resolution FABMS (HRFABMS) were obtained with a JEOL JMS-BU20 spectrometer using glycerol as the matrix. Electron-impact mass spectra (EIMS) and HREIMS were recorded on a JEOL JMS-GC mate spectrometer (70 eV) using a direct inlet system. Silica gel (silica gel 60, 230–400 mesh) (Merck), Diaion HP-20 (Mitsubishi Chemical Co., Tokyo, Japan), and

* To whom correspondence should be addressed. Fax: +81-3-3293-7572. E-mail: akihisa@chem.cst.nihon-u.ac.jp.

[‡] College of Science and Technology, Nihon University.

[§] Kyoto Prefectural University of Medicine.

[‡] Ichimaru Pharcos Co. Ltd.

[#] College of Pharmacy, Nihon University.

octadecyl silica (Chromatorex-ODS, 100–200 mesh) (Fuji Silysia Chemical, Ltd., Aichi, Japan) were used for open column chromatography. GLC was performed using a 30 m × 0.3 mm i.d. DB-17 fused-silica capillary column at 275 °C (J & W Scientific, Folsom, CA). Reversed-phase preparative high-performance liquid chromatography (HPLC) was carried out on a 25 cm × 1.0 cm i.d. Pegasil ODS II octadecyl silica gel column (Senshu Scientific Co., Ltd., Tokyo, Japan) at 25 °C, eluting with MeOH at 3 mL/min (HPLC I), MeOH–H₂O (7:3, v/v) at 2 mL/min (HPLC II), and MeOH–H₂O (6:4, v/v) at 2 mL/min (HPLC III) as mobile phase. Hydrolysis of the triterpene dibenzoate was performed with 5% (w/v) KOH in MeOH under reflux for 2 h. Acid hydrolysis of triterpene glycoside was performed with 1 M H₂SO₄–MeOH for 2 h under reflux on a water bath.

Chemicals and Materials. Samples of the fruit of *M. grosvenori* Swingle (Cucurbitaceae) were collected in China in September 1999. A voucher specimen has been deposited in the college of Science and Technology, Nihon University. Compounds were purchased as follows: TPA from ChemSyn Laboratories (Lenexa, KS); the EBV cell culture reagent and *n*-butyric acid from Nacalai Tesque, Inc. (Kyoto, Japan). Six compounds—karounidiol [D:C-friedo-oleana-7,9(11)-diene-3 α ,29-diol] and its 3-benzoate (**3**) (**5**), isomultiflorenol [D:C-friedo-olean-8-en-3 β -ol] (**4**) and 5-dehydrokarounidiol [D:C-friedo-olean-5,7,9(11)-triene-3 α ,29-diol] (**6**), β -amyrin (olean-12-en-3 β -ol) (**5**) (**7**), and 10 α -cucurbitadienol (10 α -cucurbita-5,24-dien-3 β -ol; **6**) (**8**)—were used as the reference specimens.

Extraction and Isolation. Air-dried and powdered *M. grosvenori* fruit (2 kg) was extracted with 99% ethanol (EtOH) under reflux. Evaporation of the solvent under reduced pressure yielded the EtOH extract (108 g), and the extract was partitioned into ethyl acetate (EtOAc)/H₂O (1:1, v/v) mixture. The H₂O phase was then extracted with *n*-butanol (*n*-BuOH), which gave *n*-BuOH and H₂O phases. Removal of the solvent under reduced pressure from the EtOAc, *n*-BuOH, and H₂O phases yielded EtOAc (10.0 g), *n*-BuOH (16.7 g), and H₂O (80.1 g) fractions, respectively. The EtOAc fraction was further partitioned with *n*-hexane/MeOH/H₂O (95:95:10, v/v/v), which yielded *n*-hexane (4.9 g) and MeOH/H₂O (4.8 g) fractions.

***n*-Hexane Soluble Fraction.** The *n*-hexane soluble fraction was chromatographed on a silica gel (200 g) column with a stepwise gradient of *n*-hexane/EtOAc [1:0 (0.4 L), 95:5 (2.0 L), 9:1 (2.6 L), 4:1 (1.4 L), 1:1 (1.2 L)] as eluants, which yielded fractions containing triterpene dibenzoates (62 mg; fraction HA), and triterpene monobenzoate and triterpene mono-ols (36 mg; fraction HB). Preparative HPLC (HPLC I) of fraction HA gave 5-dehydrokarounidiol dibenzoate (2.7 mg; **1**) and karounidiol dibenzoate (11.4 mg; **2**), and fraction HB yielded **3** (3.0 mg), **4** (3.2 mg), **5** (1.0 mg), and **6** (7.8 mg).

MeOH/H₂O Soluble Fraction. The MeOH/H₂O fraction (4.8 g) was subjected to Diaion HP-20 column chromatography using H₂O–MeOH (1:1 → 0:1, v/v) to give fractions MA–MC. Fraction MB (80% MeOH eluate; 1.2 g) was further separated by Chromatorex-ODS column chromatography followed by preparative HPLC to give mogrol (61 mg; *t*_R = 62.8 min in HPLC II; **7**) and five triterpene monoglycosides, 5 α ,6 α -epoxymogroside I E₁ (3.3 mg; *t*_R = 20.0 min; **8**), 11-oxomogroside I A₁ (31 mg; *t*_R = 40.4 min; **9**), 11-oxomogroside I E₁ (6.5 mg; *t*_R = 28.8 min; **10**), mogroside I A₁ (218 mg; *t*_R = 37.6 min; **11**), and mogroside I E₁ (172 mg; *t*_R = 26.4 min; **12**).

***n*-BuOH Soluble Fraction.** The *n*-BuOH fraction (16.7 g) was subjected to Diaion HP-20 column chromatography using H₂O–MeOH (1:1 → 0:1, v/v) to give fractions BA–BC. Fraction BB (80% MeOH eluate; 7.4 g) was further separated by preparative HPLC to give two triterpene glycosides, mogroside II E (917 mg; *t*_R = 53.2 min in HPLC III; **13**) and mogroside III (405 mg; *t*_R = 36.0 min; **14**).

H₂O Soluble Fraction. The H₂O fraction (80.1 g) was subjected to Diaion HP-20 column chromatography using H₂O–MeOH (1:0 → 0:1, v/v) to give fractions WA–WD. Fraction WB (50% MeOH eluate; 9.8 g) was further separated by Chromatorex-ODS column chromatography followed by HPLC to give five triterpene glycosides, siamenoside I (90 mg; *t*_R = 23.1 min in HPLC III; **15**), mogroside IV A (408 mg; *t*_R = 28.0 min; **16**), mogroside IV E (352 mg; *t*_R = 30.8 min; **17**), 11-oxomogroside V (366 mg; *t*_R = 14.9 min; **18**), and mogroside V (2714 mg; *t*_R = 19.6 min; **19**).

Identification and Characterization. Identification of four triterpenoids, **3**–**6**, was performed by chromatographic (HPLC and GLC) and spectroscopic (MS and ¹H NMR) comparison with reference compounds. The following 11 compounds were identified by spectral comparison with literature: mogrol [(24*R*)-cucurbit-5-ene-3 β ,11 α ,24,25-tetrol; **7**] (**2**), 11-oxomogroside I E₁ [(24*R*)-cucurbit-5-en-11-one-3 β ,24,25-triol 3-*O*- β -D-glucopyranoside; cabenoside D; **10**] (**3**), mogroside I A₁ [(24*R*)-cucurbit-5-ene-3 β ,11 α ,24,25-tetrol 24-*O*- β -D-glucopyranoside; **11**] (**3**), mogroside I E₁ [(24*R*)-cucurbit-5-ene-3 β ,11 α ,24,25-tetrol 3-*O*- β -D-glucopyranoside; **12**] (**3**), mogroside II E [(24*R*)-cucurbit-5-ene-3 β ,11 α ,24,25-tetrol 3,24-di-*O*- β -D-glucopyranoside; **13**] (**3**), mogroside III [3-*O*- β -D-glucopyranosyl (24*R*)-cucurbit-5-ene-3 β ,11 α ,24,25-tetrol 24-*O*- β -D-glucopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside; **14**] (**9**), siamenoside I {3-*O*- β -D-glucopyranosyl (24*R*)-cucurbit-5-ene-3 β ,11 α ,24,25-tetrol 24-*O*- β -D-glucopyranosyl-(1 \rightarrow 2)-[β -D-glucopyranosyl-(1 \rightarrow 6)]- β -D-glucopyranoside; **15**} (**10**), mogroside IV A [(24*R*)-cucurbit-5-ene-3 β ,11 α ,24,25-tetrol 3,24-di-*O*- β -D-glucopyranosyl-(1 \rightarrow 6)- β -D-glucopyranoside; **16**] (**3**), mogroside IV E [3-*O*- β -D-glucopyranosyl-(1 \rightarrow 6)- β -D-glucopyranosyl (24*R*)-cucurbit-5-ene-3 β ,11 α ,24,25-tetrol 24-*O*- β -D-glucopyranosyl-(1 \rightarrow 2)- β -D-glucopyranoside; **17**] (**3**, **11**), 11-oxomogroside V {3-*O*- β -D-glucopyranosyl-(1 \rightarrow 6)- β -D-glucopyranosyl (24*R*)-cucurbit-5-en-11-one-3 β ,24,25-triol 24-*O*- β -D-glucopyranosyl-(1 \rightarrow 2)-[β -D-glucopyranoside-(1 \rightarrow 6)]- β -D-glucopyranoside; **18**} (**10**), and mogroside V {3-*O*- β -D-glucopyranosyl-(1 \rightarrow 6)- β -D-glucopyranosyl (24*R*)-cucurbit-5-ene-3 β ,11 α ,24,25-tetrol 24-*O*- β -D-glucopyranosyl-(1 \rightarrow 2)-[β -D-glucopyranoside-(1 \rightarrow 6)]- β -D-glucopyranoside; **19**} (**2**). Characterization of four new triterpenoids, **1**, **2**, **8**, and **9**, was performed by spectroscopic methods and, in part, by chemical correlation with known compounds. The MS and ¹H NMR data of **1** and **2**, the MS data of **8** and **9**, and the ¹H and ¹³C NMR data of **12**, which was characterized for the first time as the natural product in this study, are described below. The ¹³C and ¹H NMR spectral data along with heteronuclear multiple bond correlation (HMBC) spectroscopy data for **8** and **9** are shown in Table 1.

5-Dehydrokarounidiol dibenzoate (1): amorphous solid; UV λ_{\max} 304, 314, 330 nm; IR ν_{\max} 1720 and 1270 (OBz), 1600, 1582, and 709 (C₆H₅), 814 (>C=CH–) cm^{–1}; EIMS, *m/z* (relative intensity) 646 [M]⁺ (4), 524 (10), 509 (6), 402 (2), 387 (6), 373 (8), 347 (6), 312 (41), 294 (30), 284 (26), 269 (28), 251 (32), 241 (31), 237 (21), 225 (28), 223 (30), 215 (26), 189 (26), 175 (29), 165 (32), 147 (42), 135 (38), 123 (52), 109 (70), 105 (100); HREIMS, *m/z* 646.4032 [M]⁺ (calcd for C₄₄H₅₄O₄ 646.4022); ¹H NMR (CDCl₃) δ 0.88, 1.07, 1.11, 1.14, 1.17, 1.23, 1.29 (each 3H and s, unassigned), 4.12 and 4.17 (each 1H, d, *J* = 13.8 Hz, H-29), 4.99 (1H, br s, *W*_{1/2} = 7.3 Hz, H-3 α), 5.37 (1H, m, H-11), 5.66 (1H, d, *J* = 6.0 Hz, H-7), 5.91 (1H, d, *J* = 6.0 Hz, H-6), 7.28 (2H, ddt, *J* = 7.8, 7.8, 1.5 Hz), 7.42 (2H, ddt, *J* = 7.3, 7.3, 1.5 Hz), 7.44 (1H, ddt, *J* = 7.3, 7.8, 1.5 Hz), 7.52 (1H, ddt, *J* = 7.3, 7.3, 1.5 Hz), 7.90 (2H, dt, *J* = 7.3, 1.5 Hz), and 8.06 (2H, dt, *J* = 7.3, 1.5 Hz).

Karounidiol dibenzoate (2): amorphous solid; UV λ_{\max} 230, 235, 245 nm; IR ν_{\max} 1722 and 1270 (OBz), 1602, 1584, and 709 (C₆H₅), 814 (>C=CH–) cm^{–1}; EIMS, *m/z* (relative intensity) 648 [M]⁺ (13), 526 (79); [M]⁺ – PhCOOH, 511 (19), 404 (10); [M]⁺ – 2PhCOOH, 389 (24), 375 (3); ABC ring + C-16, C-27, 361 (3), 349 (2), 293 (5), 279 (6), 267 (6), 253 (35), 239 (11), 227 (17); *m/z* 375 – PhCOOH, 213 (10), 197 (10), 185 (13), 171 (14), 159 (17), 145 (14), 121 (15), 105 (100), 95 (27), 77 (28); HREIMS *m/z* 648.4179 [M]⁺ (calcd for C₄₄H₅₆O₄ 648.4178); ¹H NMR (CDCl₃) δ 0.92, 0.92, 0.95, 0.99, 1.06, 1.11, and 1.13 (each 3H and s, unassigned), 4.13 and 4.16 (each 1H, d, *J* = 13.8 Hz, H-29), 4.91 (1H, br s, *W*_{1/2} = 7.3 Hz, H-3 α), 5.25 (1H, m, H-11), 5.54 (1H, m, H-7), 7.30 (2H, ddt, *J* = 7.6, 7.6, 1.5 Hz), 7.43 (2H, ddt, *J* = 7.6, 7.6, 1.5 Hz), 7.45 (1H, ddt, *J* = 7.6, 7.6, 1.5 Hz), 7.53 (1H, ddt, *J* = 7.6, 7.6, 1.5 Hz), 7.94 (2H, dt, *J* = 7.6, 1.5 Hz), and 8.08 (2H, dt, *J* = 7.6, 1.5 Hz).

5 α ,6 α -Epoxyogroside I E₁ [(24*R*)-5 α ,6 α -epoxycucurbit-3 β ,11 α -24,25-tetrol 3-*O*- β -D-glucopyranoside] (8): amorphous solid; IR ν_{\max} 3423 (OH) cm^{–1}; HRFABMS *m/z* 677.4241 [M + Na]⁺ (calcd for C₃₆H₆₂O₁₀Na, 677.4241); ¹H and ¹³C NMR data, see Table 1.

11-Oxomogroside I A₁ [(24*R*)-cucurbit-5-en-11-one-3 β ,24,25-triol 24-*O*- β -D-glucopyranoside] (9): amorphous solid; IR ν_{\max} 3409 (OH),

Table 1. ^{13}C , ^1H , and HMBC NMR Spectral Data for Two Cucurbitane Glycosides, **8** and **9**, from the Fruit of *Momordica grosvenori* ($\text{C}_5\text{D}_5\text{N}$)

C no.	8			9		
	δ_{C}	δ_{H}^a	HMBC (H to C)	δ_{C}	δ_{H}^a	HMBC (H to C)
1	20.5	2.40 (α), 3.08 (β)		21.3	1.64 (α), 2.06 (β)	
2	30.7	2.12 (α), 2.42 (β)		29.8	1.95 (α), 1.88 (β)	
3	87.1	3.74 (br s, $W_{1/2} = 7.2$)	1, 5	75.6	3.72 (br s, $W_{1/2} = 7.2$)	
4	41.3			41.9		
5	67.5			141.5		
6	53.0	3.19 (br d, 5.8)	4, 5, 7	119.0	5.69 (d, 5.8)	4, 7, 8, 10
7	23.6	1.67 (α), 2.20 (β)	9	24.2	2.35 (α), 1.86 (β)	
8	42.5	1.58	6, 7, 9, 10, 11, 14	44.1	1.89	7, 8, 10, 19, 30
9	40.0			49.2		
10	34.5	2.69 (br d, 9.0)	9, 11, 19	36.0	2.53	
11	78.9	4.02 (br d, 10.3)	8	213.9		
12	40.9	2.13 (α), 2.04 (β)	9, 11, 13, 14, 18	48.8	2.97 (α), 2.53 (β)	
13	46.4			49.1		
14	49.8			49.7		
15	34.4	1.18 (α), 1.06 (β)	9, 14, 16	34.6	1.18 (α), 1.32 (β)	
16	30.0	1.35 (α), 1.28 (β)	14, 20	29.5	1.78 (α), 1.70 (β)	
17	51.2	1.66	14, 20, 22	49.9	1.76	14, 20, 22
18	17.0	0.85 (s)	12, 13, 14, 17	17.0	0.76 (s)	12, 13, 14, 17, 21
19	25.0	1.51 (s)	8, 9, 10	20.2	1.28 (s)	1, 8, 9, 10, 11
20	36.4	1.59		36.6	1.45	
21	18.9	1.01 (d, 6.4)	17, 20, 22, 23	18.6	0.91 (d, 6.4)	17, 20, 22
22	34.1	1.65, 1.82	20, 21, 24, 26, 27	33.3	1.81, 1.92	
23	29.0	1.83 (2H)	20, 24, 25, 26, 27	28.1	2.15 (2H)	
24	79.1	3.77 (br d, 10.0)	25	90.7	3.89 (br d, 8.5)	22, 23, 25, 26, G1
25	72.7			71.8		
26	25.9	1.57 (s)	23, 24, 25, 27	25.4	1.47 (s)	24, 25, 27
27	26.2	1.53 (s)	22, 23, 24, 25, 26	27.0	1.42 (s)	23, 24, 25, 26
28	21.4	1.22 (s)	3, 4, 5, 29	28.7	1.17 (s)	4, 5, 29
29	25.8	1.21 (s)	3, 4, 5, 28	26.3	1.43 (s)	2, 3, 4, 5, 6, 28
30	20.7	0.91 (s)	8, 13, 14, 15	18.3	0.99 (s)	8, 9, 12, 13, 14, 15
G1	106.4	4.91 (d, 7.6)	3, G3, G5	105.9	5.00 (d, 7.8)	24, G3, G5
G2	75.8	4.01 (dd, 7.6, 7.6)	G3	75.4	4.05 (dd, 7.8, 7.8)	G1, G3
G3	78.4	4.22 (dd, 7.6, 7.6)	G4	78.6	4.24 (dd, 7.8, 7.8)	G2, G4, G5
G4	71.7	4.20 (dd, 7.6, 7.6)	G3, G5	72.0	4.22 (dd, 7.8, 7.8)	G2, G3, G5, G6
G5	78.4	3.93 (m)	G1	78.5	4.02 (m)	G1, G3
G6	63.0	4.37 (dd, 5.4, 12.4)	G5	62.7	4.35 (dd, 5.5, 12.0)	G5
		4.51 (dd, 2.5, 12.4)	G5		4.56 (dd, 2.5, 12.0)	G5

^a Numbers in parentheses denote J values (hertz).

1691 ($\text{C}=\text{O}$) cm^{-1} ; HRFABMS m/z 635.4120 [$\text{M} - \text{H}$]⁻ (calcd for $\text{C}_{36}\text{H}_{59}\text{O}_9$, 635.4159); ^1H and ^{13}C NMR data, see **Table 1**.

Mogroside I (**12**): ^1H NMR ($\text{C}_5\text{D}_5\text{N}$) δ 0.92 (3H, s, H-28), 0.93 (3H, s, H-18), 0.99 (3H, d, $J = 6.4$ Hz, H-21), 1.22 (3H, s, H-19), 1.39 (3H, s, H-26), 1.40 (3H, s, H-30), 1.43 (3H, s, H-29), 1.46 (3H, s, H-27), 3.68 (1H, br s, H-3), 3.76 (1H, br d, $J = 6.8$ Hz, H-24), 4.19 (1H, m, H-11), 5.50 (1H, d, $J = 5.1$ Hz, H-6), 4.88 (1H, d, $J = 8.0$ Hz, H-G1), 4.01 (1H, m, H-G2), 4.21 (2H, m, H-G3, H-G4), 3.93 (1H, m, H-G5), 4.37 (1H, dd, $J = 4.4, 9.2$ Hz), and 4.51 (1H, dd, $J = 2.0, 9.2$ Hz) (H-G6); ^{13}C NMR ($\text{C}_5\text{D}_5\text{N}$) C-1 (δ_{C} 26.8), C-2 (29.5), C-3 (87.9), C-4 (42.4), C-5 (144.2), C-6 (118.5), C-7 (24.6), C-8 (43.5), C-9 (40.2), C-10 (36.9), C-11 (77.8), C-12 (41.1), C-13 (49.5), C-14 (49.8), C-15 (34.5), C-16 (28.5), C-17 (51.0), C-18 (17.0), C-19 (26.2), C-20 (36.3), C-21 (18.9), C-22 (34.2), C-23 (29.0), C-24 (79.0), C-25 (72.7), C-26 (25.9), C-27 (26.3), C-28 (27.7), C-29 (26.3), C-30 (19.3), C-G1 (107.3), C-G2 (75.5), C-G3 (78.7), C-G4 (71.8), C-G5 (78.1), C-G6 (63.1). The ^1H and ^{13}C NMR signal assignments of **12** were performed with the aid of ^{13}C DEPT NMR, $^1\text{H}-^1\text{H}$ correlation spectroscopy (COSY), ^1H -detected multiple quantum coherence (HMQC), heteronuclear multiple bond correlation (HMBC), and phase-sensitive nuclear Overhauser and exchange spectroscopy (NOESY) experiments.

In Vitro EBV-EA Activation Experiment. The inhibition of EBV-EA activation was assayed using Raji cells (EBV genome-carrying human lymphoblastoid cells; nonproducer type), cultivated in 10% fetal bovine serum (FBS) RPMI-1640 medium (Sigma, St. Louis, MO). The indicator cells (Raji cells; 1×10^6 cells/mL) were incubated in 1 mL of the medium containing 4 mM *n*-butyric acid as an inducer, 32 pM TPA [20 ng/mL in dimethyl sulfoxide (DMSO)], and a known amount (32, 16, 3.2, 0.32 nM) of the test compound at 37 °C in a CO_2 incubator. After 48 h, the cell suspensions were centrifuged at 1000 rpm for 10

min, and the supernatant was removed. The activated cells were stained with high-titer EBV-EA-positive sera from nasopharyngeal carcinoma patients, and the conventional indirect immunofluorescence technique was employed for detection. In each assay, at least 500 cells were counted, and the experiments were repeated three times. The average extent of EA induction was determined and compared with that on positive control experiments in which the cells were treated with *n*-butyric acid plus TPA, where the extent of EA induction was ordinarily more than around 40%. The viability of treated Raji cells was assayed by the Trypan blue staining method (12).

RESULTS AND DISCUSSION

Two new triterpene benzoates, **1** and **2**, and two new triterpene glycosides, **8** and **9**, along with 15 known triterpenoids (one triterpene benzoate, **3**; three triterpene monols, **4**–**6**; one triterpene aglycon, **7**; and 10 triterpene glycosides, **10**–**19**), were isolated from the EtOH extract of *M. grosvenori* fruit in this study. Compound **12** was previously synthesized from **19** by maltase hydrolysis (3), but this study found naturally occurring **12**. A pentaglycoside, **19**, the most relevant sweet principle of *M. grosvenori* fruit, followed by a diglycoside, **13**, constituted the predominant triterpenoid components of the extract. Characterization of two new triterpene dibenzoates (**1**, **2**) and two new triterpene glycosides (**8**, **9**) is described below.

5-Dehydrokarounidiol Dibenzoate (1). Compound **1** ($\text{C}_{44}\text{H}_{54}\text{O}_4$) had two benzoyl groups [δ_{H} 7.28 (2H, t), 7.42 (2H, t), 7.44 (1H, dt), 7.52 (1H, dt), 7.90 (2H, dt), and 8.06 (2H, dt)],

Table 2. Percentage of Epstein–Barr Virus Early Antigen Induction in the Presence of the Extracts of *Momordica grosvenori* Fruit with Respect to a Positive Control (100%)^a

extract	concentration ($\mu\text{g/mL}$)		
	100	10	1
ethanol extract	10.4 (70)	46.7	97.9
<i>n</i> -hexane soluble fraction	7.0 (70)	43.7	95.1
MeOH/H ₂ O soluble fraction	9.2 (70)	47.2	96.0
<i>n</i> -BuOH soluble fraction	19.5 (50)	59.0	100
H ₂ O soluble fraction	21.4 (60)	62.4	100

^a Values represent relative percentages to the positive control value. TPA (32 pmol, 20 ng) = 100%. Values in parentheses are viability percentages of Raji cells.

11-Oxomogroside I A₁ (9). Compound **9** was assigned a molecular formula of C₃₆H₆₀O₉, as determined from its ¹³C DEPT NMR data and [M – H][–] ion at *m/z* 635.4120 in the HRFABMS (negative-ion mode). The ¹H NMR spectrum (Table 1) of **9** exhibited signals due to seven tertiary methyls [δ_{H} 0.76, 0.99, 1.17, 1.28, 1.42, 1.43, and 1.47], one secondary methyl (δ_{H} 0.91, d, *J* = 6.4 Hz), two oxymethines [δ_{H} 3.72 (br s) and 3.87 (d, *J* = 8.8 Hz)], an olefin methine (δ_{H} 5.69, d, *J* = 5.8 Hz), and an anomeric proton [δ_{H} 5.00 (d, *J* = 7.8 Hz)], along with other ¹H signals due to a glucose moiety. Comparison of the ¹H and ¹³C NMR data of **9** with those of 11-oxomogrol [bryodulcosigenin; (24*R*)-cucurbit-5-en-11-one-3 β ,24,25-triol; **20**] (**14**) suggested **9** to be the 24-*O*-glucoside of **20**. The presence of a long-range ³J_{C–H} correlation between the anomeric ¹H signal (H–G1, δ_{H} 5.00), together with the ¹³C signal of C-24 (δ_{C} 90.7) observed in the HMBC spectrum of **9**, is consistent with a glucosidic linkage at C-24. Acid hydrolysis of **9** gave **20**; hence, **9** was formulated as (24*R*)-cucurbit-5-en-11-one-3 β ,24,25-triol 24-*O*- β -D-glucopyranoside (11-oxomogroside I A₁).

Inhibitory Effect on EBV-EA Induction. The EtOH extract of *M. grosvenori* fruit, the *n*-hexane, MeOH/H₂O, *n*-BuOH, and H₂O soluble fractions obtained from the EtOH extract, 18 triterpenoids (**2–19**) isolated from the fractions of the EtOH extract, and an aglycon, **20**, obtained from **9** by acid hydrolysis, were evaluated for their inhibitory effects on the induction of EBV-EA by TPA in Raji cells as a primary screening test for antitumor promoters. The inhibitory effects of the EtOH extract and the four fractions are shown in Table 2 and those of the 19 triterpenoids in Table 3, along with comparable data for β -carotene, a vitamin A precursor that has been studied intensively in cancer chemoprevention using animal models (15). The EtOH extract and the four fractions showed inhibitory effects against EBV activation with 79–93% inhibition at 100 $\mu\text{g/mL}$, and among the four fractions, the least polar *n*-hexane fraction exhibited the most potent inhibition (93% inhibition), whereas the most polar H₂O fraction showed the least inhibition (79% inhibition) (Table 2).

All of the triterpenoids from *M. grosvenori* fruit extract tested showed potent inhibitory effects on EBV-EA induction (70–100% inhibition at 1×10^3 mol ratio/TPA) while preserving the high viability (60–70%) of Raji cells, and most of them were equivalent to or more potent than β -carotene (Table 3). Among these, one triterpene monol (**6**), two triterpene aglycons (**7**, **20**), and six mono- and diglycosides (**8–13**) showed potent inhibitory effects on EBV-EA activation at 1×10 mol ratio/TPA (2–11% inhibition) and exhibited remarkably high inhibitory effects at a high concentration (97–100% inhibition at 1×10^3 mol ratio). Benzoylation of the hydroxyl group(s) of triterpene alcohols, and tri-, tetra-, and pentaglycosylation of cucurbitane aglycons led to a slight reduction of the inhibitory

Table 3. Percentage of Epstein–Barr Virus Early Antigen Induction in the Presence of **2–20** with Respect to a Positive Control (100%)^a

compound	concentration (mol ratio/TPA)			
	1000	500	100	10
2 karounidiol dibenzoate	29.7 (60)	63.7	89.0	100
3 karounidiol 3-benzoate	15.8 (70)	54.5	79.4	100
4 isomultiflorenol	2.6 (70)	45.2	74.6	100
5 β -amyryn	6.9 (70)	48.3	75.2	100
6 10 α -cucurbitadienol	0 (70)	22.7	70.3	91.5
7 mogrol	0 (70)	27.3	71.6	90.2
8 5 α ,6 α -epoxymogroside I E ₁	0 (60)	25.2	68.1	92.0
9 11-oxomogroside I A ₁	0 (70)	29.0	77.4	97.2
10 11-oxomogroside I E ₁	0 (60)	26.1	69.3	94.1
11 mogroside I A ₁	0 (70)	28.3	76.5	98.4
12 mogroside I E ₁	3.1 (70)	29.0	73.2	96.7
13 mogroside II E	0 (70)	32.1	72.3	96.2
14 mogroside III	4.6 (60)	40.3	76.7	100
15 siamenoside I	10.0 (60)	50.2	81.3	100
16 mogroside IV A	8.5 (70)	33.7	76.7	100
17 mogroside IV E	9.2 (70)	31.6	75.6	100
18 11-oxomogroside V	12.6 (60)	51.3	83.0	100
19 mogroside V	5.1 (60)	42.3	78.9	100
20 11-oxomogrol	0 (70)	23.8	69.3	88.9
β -carotene ^b	8.6 (70)	34.2	82.1	100

^a Values represent percentages relative to the positive control value. TPA (32 pmol, 20 ng) = 100%. Values in parentheses are viability percentages of Raji cells. ^b Reference compound.

effects, as observed for two triterpene benzoates (**2**, **3**) (16) and six tri-, tetra-, and pentaglycosides (**14–19**), which exhibited 70–95% inhibition at 1×10^3 mol ratio. Free triterpene monols, **4–6**, and other uncharacterized components, but not the benzoates **1–3**, might be responsible for the strong inhibitory effect of the least polar *n*-hexane fraction (Table 2). The inhibitory effects against EBV-EA induction have been demonstrated to closely parallel those against tumor promotion in vivo (17, 18), and the cucurbitane glycosides, the sweet principles of *M. grosvenori* fruit, and the other triterpenoid constituents in the extract of *M. grosvenori* fruit are, therefore, suggested to be valuable antitumor promoters (potential cancer chemopreventive agents).

ACKNOWLEDGMENT

We thank Miss Ikue Tamakawa and Mr. Akihiro Iwasaka for technical assistance.

LITERATURE CITED

- (1) Takemoto, T.; Arihara, S.; Nakajima T.; Okuhira M. Studies on the constituents of Fructus Momordicae. I. *Yakugaku Zasshi* **1983**, *103*, 1151–1154.
- (2) Takemoto, T.; Arihara, S.; Nakajima T.; Okuhira M. Studies on the constituents of Fructus Momordicae. II. *Yakugaku Zasshi* **1983**, *103*, 1155–1166.
- (3) Takemoto, T.; Arihara, S.; Nakajima T.; Okuhira M. Studies on the constituents of Fructus Momordicae. III. *Yakugaku Zasshi* **1983**, *103*, 1167–1173.
- (4) Ukiya, M.; Akihisa, T.; Yasukawa, K.; Tokuda, H.; Toriumi, M.; Koike, K.; Kimura, Y.; Nikaido, T.; Aoi, W.; Nishino, H.; Takido, M. Anti-inflammatory and anti-tumor-promoting effects of cucurbitane glycosides from the roots of *Bryonia dioica*. *J. Nat. Prod.* **2002**, *65*, 179–183.
- (5) Akihisa, T.; Tamura, T.; Matsumoto, T.; Eggleston, E. S.; Kokke, W. C. M. C.; Shimizu, N. Karounidiol [D:C-friedo-Oleana-7,9-(11)-diene-3 α ,29-diol] and its 3-*O*-benzoate: novel pentacyclic triterpenes from *Trichosanthes kirilowii*. X-Ray molecular structure of karounidiol diacetate. *J. Chem. Soc., Perkin Trans. I* **1988**, 439–443.

- (6) Akihisa, T.; Kokke, W. C. M. C.; Krause, J. A.; Eggleston, D. S.; Katayama S.; Kimura, Y.; Tamura T. 5-Dehydrokarounidiol [D:C-friedooleana-5,7,9(11)-triene-3 α ,29-diol], a novel triterpene from *Trichosanthes kirilowii* MAXIM. *Chem. Pharm. Bull.* **1992**, *40*, 3280–3283.
- (7) Akihisa, T.; Yasukawa, K.; Kimura, Y.; Takase, S.; Yamanouchi, S.; Tamura, T. Triterpene alcohols from camellia and sasanqua oils and their anti-inflammatory effects. *Chem. Pharm. Bull.* **1997**, *45*, 2016–2023.
- (8) Akihisa, T.; Kimura, Y. Sterols and triterpenes of the family Cucurbitaceae. *Rec. Res. Dev. Phytochem.* **1997**, *1*, 339–348.
- (9) Matsumoto, K.; Kasai, R.; Ohtani, K.; Tanaka, O. Minor cucurbitane-glycosides from fruits of *Siraitia grosvenori* (Cucurbitaceae). *Chem. Pharm. Bull.* **1990**, *38*, 2030–2032.
- (10) Kasai, R.; Nie, Rui-Lin; Nashi, K.; Ohtani, K.; Zhou, J.; Tao, G.; Tanaka, O. Sweet cucurbitane-glycosides from fruits of *Siraitia siamensis* (chi-zi luo-han-guo), a Chinese folk medicine. *Agric. Biol. Chem.* **1989**, *53*, 3347–3349.
- (11) Jian-yong, S.; Di-hua, C.; Qi, C.; Lian-gang, S. Isolation and determination of cucurbitane-glycosides from fresh fruits of *Siraitia grosvenorii*. *Acta Bot. Sin.* **1996**, *38*, 489–494.
- (12) Takaishi, Y.; Ujita, K.; Tokuda, H.; Nishino, H.; Iwashima, A.; Fujita, T. Inhibitory effects of dihydroagarofuran sesquiterpenes on Epstein–Barr virus activation. *Cancer Lett.* **1992**, *65*, 19–26.
- (13) Leitão, S. G.; Kaplan, M. A. C.; Monache, F. D.; Akihisa, T.; Tamura, T. Sterols and sterol glucosides from the *Aegiphila* species. *Phytochemistry* **1992**, *31*, 2813–2817.
- (14) Oobayashi, K.; Yoshikawa, K.; Arihara, S. Structural revision of bryonoside and structure elucidation of minor saponins from *Bryonia dioica*. *Phytochemistry* **1992**, *31*, 943–946.
- (15) Murakami, A.; Ohigashi, H.; Koshimizu, K. Anti-tumor promotion with food phytochemicals: A strategy for cancer chemoprevention. *Biosci. Biotech. Biochem.* **1996**, *60*, 1–8.
- (16) Akihisa, T.; Tokuda, H.; Ichiishi, E.; Mukainaka, T.; Toriumi, M.; Ukiya, M.; Yasukawa, K.; Nishino, H. Anti-tumor promoting effects of multiflorane-type triterpenoids and cytotoxic activity of karounidiol against human cancer cell lines. *Cancer Lett.* **2001**, *173*, 9–14.
- (17) Konoshima, T.; Takasaki, M.; Tokuda, H.; Masuda, K.; Arai, Y.; Shiojima, K.; Ageta, H. Anti-tumor-promoting activities of triterpenoids from ferns. I. *Biol. Pharm. Bull.* **1996**, *19*, 962–965.
- (18) Takasaki, M.; Konoshima, T.; Tokuda, H.; Masuda, K.; Arai, Y.; Shiojima, K.; Ageta, H. Anti-carcinogenic activity of *Taraxacum* plant. II. *Biol. Pharm. Bull.* **1999**, *22*, 606–610.

Received for review June 5, 2002. Revised manuscript received August 13, 2002. Accepted August 22, 2002. This work was supported in part by a grant, “Research and Development of Nanoscience”, from the Ministry of Education, Science, Sports and Culture to promote multidisciplinary research and by a Grant-in-Aid from the Ministry of Education, Science, Sports and Culture, and the Ministry of Health and Welfare, Japan.

JF0206320